CLINICAL_TRIALS
trial_result
· 2016-06-01
Clinical Trial Update: Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes [Phase 3]
Summary
A Phase 3 trial of TAK-875 added to glimepiride in type 2 diabetes was terminated, with results posted in 2016.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Takeda | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: TERMINATED | Results posted: 2016-06-01